Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05775042
PHASE2
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
Sponsor: Keymed Biosciences Co.Ltd
View on ClinicalTrials.gov
Summary
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.
Official title: A Phase II Clinical Study Evaluating the Efficacy and Safety of CM338 Injection in Subjects With Immunoglobulin A Nephropathy
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2023-05-08
Completion Date
2027-06-30
Last Updated
2024-10-15
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
CM338
CM338 injection
Locations (1)
Peking University First Hospital
Beijing, Beijing Municipality, China